Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Conditions
Aggressive Non-Hodgkin Lymphoma · ALK-Positive Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements · High Grade B-Cell Lymphoma, Not Otherwise Specified · Primary Mediastinal Large B-Cell Lymphoma · T-Cell/Histiocyte-Rich Large B-Cell Lymphoma · Gray-Zone Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Principal Investigator (Ryan Lynch)
Study leads
Ryan Lynch
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium